search
Back to results

Embolization in Splenic Trauma (ELSA)

Primary Purpose

Trauma to the Spleen

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Splenic artery embolization with vascular embolic coils
Splenic artery embolization with vascular embolic plugs
Sponsored by
University of Alabama at Birmingham
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Trauma to the Spleen

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients presenting to the University of Alabama at Birmingham (UAB) emergency room requiring embolization of the splenic artery

Sites / Locations

  • April Riddle

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Splenic artery embolization with vascular embolic coils

Splenic artery embolization with vascular embolic plugs

Arm Description

Outcomes

Primary Outcome Measures

Number of Participants Who Were Enrolled Within 18 Months of Study Initiation
The primary outcome of the study will be enrolling 50 participants in the study within 18 months of study initiation with adequate 30 day follow-up on all participants.

Secondary Outcome Measures

Number of Participants With Embolization Success
This outcome will be measured by the ability of the operator to deploy the required embolic with resultant stasis in the splenic artery. This will be compared between the two groups.
Number of Participants With Immediate Complications
This outcome will be measured by the number of intra-procedural complications and compared between the two groups
Number of Participants With Splenic Salvage
This outcome will be measured by splenic salvage rate at 30 days and compared between groups. Splenic salvage was defined as the absence of splenectomy in the medical record or per patient report.
Radiation Exposure
The radiation exposure during the embolization procedure for each embolic will be measured and compared.
Contrast Volume
The amount of contrast used during the procedure will be measured for each group and compared.

Full Information

First Posted
July 12, 2018
Last Updated
August 9, 2021
Sponsor
University of Alabama at Birmingham
search

1. Study Identification

Unique Protocol Identification Number
NCT03613454
Brief Title
Embolization in Splenic Trauma
Acronym
ELSA
Official Title
Embolization in Splenic Trauma (ELSA)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
February 16, 2019 (Actual)
Primary Completion Date
March 3, 2020 (Actual)
Study Completion Date
June 30, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Alabama at Birmingham

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes

5. Study Description

Brief Summary
Randomized, prospective, feasibility study to begin evaluating the efficacy, safety, and cost of using either coils or vascular plugs (VPs) for proximal splenic artery embolization in the setting of traumatic splenic injury.
Detailed Description
Splenic preservation rates are improved for participants with high-grade splenic injuries (defined as Grade III-V injuries by the American Association for the Surgery of Trauma (AAST) guidelines) when non-operative management is supplemented by image-guided, trans-catheter splenic artery embolization (SAE). SAE is currently the standard of care for hemodynamically stable participants with high-grade splenic injuries. In proximal SAE (pSAE), the mid-splenic artery is embolized between the origins of the dorsal pancreatic artery and pancreatica magna artery with either VPs or coils. This reduces the intra-splenic arterial pressure which allows the parenchyma time to heal. Splenic perfusion is maintained via a collateral pathway consisting of flow from the splenic artery proximal to the site of embolization through the smaller dorsal pancreatic artery to the transverse pancreatic artery to the pancreatica magna artery which then delivers a slower, smaller amount of blood to the splenic artery distal to the site of embolization. Additionally, collateral supply from the short gastric and gastroepiploic arteries helps to protect the spleen from infarction and/or abscess formation. pSAE is most often accomplished using either coils or VPs as the embolic agent, both of which are FDA-approved and clinically-available. Coils have a long history of efficacy and safety for embolization and are thus familiar embolic agents to most endovascular specialists. Further, coils large enough to embolize the mid-splenic artery can be deployed through a standard micro-catheter, which means they can be used in even the most tortuous splenic arteries. However, multiple coils may need to be deployed in the same patient to achieve hemostasis in the mid-splenic artery that may increase their overall cost, iodinated contrast use, procedural time, and the radiation exposure to the participant and medical staff. Additionally, given the high-flow nature of the splenic artery, even an appropriately sized coil may migrate distally. A typical pSAE using coils will involve the deployment of one helical coil followed by multiple packing coils until hemostasis is achieved. VPs attempt to overcome the limitations of coils. For example, the deployment of a single VP can typically provide hemostasis in the mid-splenic artery which theoretically reduces procedural time, contrast load, and radiation exposure. Despite this, VPs are more expensive than coils on a per unit basis and are usually less familiar devices to endovascular specialists. Another drawback of VPs is that they cannot be deployed through a standard micro-catheter but rather require the advancement of a larger, stiffer 0.035 inch system into the mid-splenic artery. This may limit their use in very tortuous splenic arteries. Currently, the selection of embolic agent for pSAE is primarily based on operator experience and preference. The embolic efficacy, technical success, and cost of using coils compared to VPs has been evaluated in other diseases; yet, to the best of our knowledge, these embolic agents have never been compared for their use in pSAE, much less in a randomized, prospective fashion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Trauma to the Spleen

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
48 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Splenic artery embolization with vascular embolic coils
Arm Type
Active Comparator
Arm Title
Splenic artery embolization with vascular embolic plugs
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
Splenic artery embolization with vascular embolic coils
Intervention Description
Splenic artery embolization with vascular embolic coils
Intervention Type
Device
Intervention Name(s)
Splenic artery embolization with vascular embolic plugs
Intervention Description
Splenic artery embolization with vascular embolic plugs
Primary Outcome Measure Information:
Title
Number of Participants Who Were Enrolled Within 18 Months of Study Initiation
Description
The primary outcome of the study will be enrolling 50 participants in the study within 18 months of study initiation with adequate 30 day follow-up on all participants.
Time Frame
Through study completion, an average of 1 year
Secondary Outcome Measure Information:
Title
Number of Participants With Embolization Success
Description
This outcome will be measured by the ability of the operator to deploy the required embolic with resultant stasis in the splenic artery. This will be compared between the two groups.
Time Frame
Through study completion, an average of 1 year
Title
Number of Participants With Immediate Complications
Description
This outcome will be measured by the number of intra-procedural complications and compared between the two groups
Time Frame
During the embolization procedure, an average of 1 hour
Title
Number of Participants With Splenic Salvage
Description
This outcome will be measured by splenic salvage rate at 30 days and compared between groups. Splenic salvage was defined as the absence of splenectomy in the medical record or per patient report.
Time Frame
30 days after procedure
Title
Radiation Exposure
Description
The radiation exposure during the embolization procedure for each embolic will be measured and compared.
Time Frame
During the embolization procedure, an average of 1 hour
Title
Contrast Volume
Description
The amount of contrast used during the procedure will be measured for each group and compared.
Time Frame
During the embolization procedure, an average of 1 hour

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients presenting to the University of Alabama at Birmingham (UAB) emergency room requiring embolization of the splenic artery
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrew J Gunn, MD
Organizational Affiliation
The University of Alabama at Birmingham
Official's Role
Principal Investigator
Facility Information:
Facility Name
April Riddle
City
Harpersville
State/Province
Alabama
ZIP/Postal Code
35078
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Embolization in Splenic Trauma

We'll reach out to this number within 24 hrs